期刊文献+

非霍奇金淋巴瘤p53蛋白表达与临床疗效及预后的相关性研究 被引量:1

下载PDF
导出
摘要 目的研究p53蛋白表达在非霍奇金淋巴瘤(NHL)临床治疗疗效判断及预后评估中的意义。方法采用免疫组织化学染色法(LSAB法)检测128例NHL患者活检石蜡组织中p53蛋白的表达,同时予CHOP方案4个或以上疗程的化疗,观察p53与化疗疗效及预后的关系。结果 p53蛋白表达阳性率为39.8%。p53蛋白阳性表达和阴性表达病例的总生存期、无瘤生存期均有统计学差异。而p53蛋白的表达对不同国际预后指数(IPI)评分患者总生存期和无瘤生存期的影响无统计学差异。结论 p53蛋白作为进展型NHL临床近期疗效的有效预测指标,对NHL预后预测意义不大。
出处 《山东医药》 CAS 北大核心 2011年第16期100-101,F0003,共3页 Shandong Medical Journal
  • 相关文献

参考文献6

  • 1Jaffe ES,Harris NL,Diebold J,et al.Wodd Health Organization claasi-fication of neoplastic diseases of the hematopoitic and lymphoid tissues:a progress report[J].Am J Clin Pathol,1999,111(Suppl 1):8-12.
  • 2Vet JA,Bringuier PP,Schanfsma HE,et al.Comparision of p53 protein overexpreasion with p53 mutation in bladder cancer:clinical and biologic aspects[J].Lab Invest,1995,73(6):837-843.
  • 3Levine AJ,Momand J,Finlay CA.The p53 tumor suppressor gene[J].Nature,1991,351 (6326):453-456.
  • 4Navaramam S,Williams GJ,Rubinger M,et al.Expression of p53 predicts treatment failure in aggressive non-Hodgkin's lymphoma[J].Leuk Lymphoma,1998,29(1-2):139-144.
  • 5Aoyagi K,Kohfuji K,Yano S,et al.The expression d proliferating cell nuclear antigen,p53,p21,and apoptosis in primary gastric lymphoma[J].Surgery,2002,132(1):20-26.
  • 6Agapé P,Copin MC,Cavrois M,et al.Implication of HTLV-Ⅰ infection,strongyloidiasis,and P53 overexpression in the development,response to treatment,and evolution of non-Hodgkin's lymphomas in an endemic area (Martinique,French West Indies)[J].J Acquit Immune Defic Syndr Hum Retrevirol,1999,20(4):394-402.

同被引文献30

  • 1No authors listed.A predictive model for aggressive non-Hodgkin's lymphomas.The International Non-Hodgkin's Lymphoma Prognostic Factors Project[J].N Engl J Med,1993,329 (14):987-994.
  • 2崔丽娟,白晓川.非霍奇金淋巴瘤预后相关因素分析[J].亍夏医科大学学报,2009,31(3)343-345.
  • 3Wei G,Yuping Z,Jun W,et al.CA125 expression in patients with non-Hodgkin's lymphoma[J].Leuk Lymphoma,2006,47 (7):1322-1326.
  • 4Vet JA,Bringuier PP,Schaafsma HE,et al.Comparision of p53 protein over expression with p53 mutation in bladder cancer:clinical and biologic aspects[J].Lab Invest,1995,73(6):837-843.
  • 5Navaramam S,Williams GJ,Rubinger M,et al.Expression of p53 predicts treatment failure in aggressive non-Hodgkins lymphoma[J].Leuk Lymphoma,1998,29 (1/2):139-144.
  • 6Aoyagi K,Kohfuji K,Yano S,et al.The expression of prolife rating cell nuclear antigen,p53,p21,and apoptosis in primary gastriclym phoma[J].Surgery,2002,132(1):20-26.
  • 7Agape P,Copin MC,Cavrois M,et al.Implication of HTLV-I infection,strongyloidiasis,and P53 over expression in the development,response to treatment,and evolution of non-Hodgkin's lymphomas in an endemic area (Mart inique,French West Indies)[J].J Acquir Immune Defic Syndr Hum Retrovirol,1999,20(4):394-402.
  • 8Ling V,Thompsont LH.Reduced permeability in CHO cell as a mechanism of resistance to colchnicines[J].J Cell Physiol,1974,83(1):103-116.
  • 9Paydas S,Ergin M,Erdogan S,et al.Thrombospondin1 (TSP-1) and Survivin(S) expression in non-Hogkin' s lymphomas[J].Leuk Res,2008,32 (2):243-250.
  • 10Sakaguchi S,Sakaguchi N,Asano M,et al.Immunologic self tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains(CD25)breakdown of a single mechanism of self tolerance causes various autoimmune diseases[J].J Immunol,1995,155(3):1151-1164.

引证文献1

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部